ESTRO 2024 - Abstract Book

S2598

Clinical - Urology

ESTRO 2024

Patients were stratified according to risk classes (data available for 98.2% of the cohort) as follow: 353 (42.8%) as favorable intermediate, 177 (21.5%) as low, 135 (16.4%) as unfavorable intermediate and 144 (17.5%) as high /very high risk. Median baseline CCI score was 4 (range 1 – 11). Diabetes mellitus (14.6%) and localized second malignancy (12.9%) were the most frequent comorbidities, followed by heart failure/myocardial infarction (7.0%) and cerebrovascular disease (6.7%).

All patients underwent UHRT in 5 fractions with a dose/fx within 6.25 and 7.25 Gy every other day. Median prostate CTV volume was 60 cc. A total of 310 (37.6%) patients received a SIB on DIL of 7.5/8 Gy fx.